JP2003516351A - コラーゲン誘導血小板凝集阻害剤 - Google Patents

コラーゲン誘導血小板凝集阻害剤

Info

Publication number
JP2003516351A
JP2003516351A JP2001543099A JP2001543099A JP2003516351A JP 2003516351 A JP2003516351 A JP 2003516351A JP 2001543099 A JP2001543099 A JP 2001543099A JP 2001543099 A JP2001543099 A JP 2001543099A JP 2003516351 A JP2003516351 A JP 2003516351A
Authority
JP
Japan
Prior art keywords
platelet aggregation
collagen
compound
induced
induced platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001543099A
Other languages
English (en)
Japanese (ja)
Inventor
ウックン、ファティ、エム．
Original Assignee
パーカー ヒューズ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーカー ヒューズ インスティテュート filed Critical パーカー ヒューズ インスティテュート
Publication of JP2003516351A publication Critical patent/JP2003516351A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
JP2001543099A 1999-11-30 2000-11-29 コラーゲン誘導血小板凝集阻害剤 Withdrawn JP2003516351A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810399P 1999-11-30 1999-11-30
US60/168,103 1999-11-30
PCT/US2000/042370 WO2001041754A2 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene

Publications (1)

Publication Number Publication Date
JP2003516351A true JP2003516351A (ja) 2003-05-13

Family

ID=22610139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001543099A Withdrawn JP2003516351A (ja) 1999-11-30 2000-11-29 コラーゲン誘導血小板凝集阻害剤

Country Status (5)

Country Link
EP (1) EP1235567A2 (fr)
JP (1) JP2003516351A (fr)
AU (1) AU4508601A (fr)
CA (1) CA2390857A1 (fr)
WO (1) WO2001041754A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623565A1 (fr) 2005-09-28 2007-04-05 Biovascular, Inc. Methodes et compositions servant a bloquer l'adherence plaquettaire et cellulaire, la migration cellulaire et l'inflammation
MX2008008642A (es) 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
EP2081435B1 (fr) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP3311818A3 (fr) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides
WO2011153514A2 (fr) 2010-06-03 2011-12-08 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2013010136A2 (fr) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
NZ702548A (en) 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
MX2015006168A (es) 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
CA2920534A1 (fr) 2013-08-12 2015-02-19 Pharmacyclics Llc Methodes de traitement d'un cancer amplifie par her2
PE20160560A1 (es) 2013-09-30 2016-06-09 Pharmacyclics Llc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
BR122023020985A2 (pt) 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0607775T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 1 beta
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
JP2002512216A (ja) * 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Ｂｔｋインヒビターならびにその同定方法および使用方法
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK

Also Published As

Publication number Publication date
WO2001041754A2 (fr) 2001-06-14
WO2001041754A8 (fr) 2003-10-23
WO2001041754A9 (fr) 2002-08-01
WO2001041754A3 (fr) 2002-03-21
CA2390857A1 (fr) 2001-06-14
AU4508601A (en) 2001-06-18
EP1235567A2 (fr) 2002-09-04

Similar Documents

Publication Publication Date Title
JP2003516351A (ja) コラーゲン誘導血小板凝集阻害剤
JP2003518023A (ja) トロンビン誘導血小板凝集の阻害剤
DE69924500T2 (de) Chinazolinderivate
Thieringer et al. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
EP1364659B1 (fr) Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
US6958220B2 (en) Inhibitors of proteasomal activity for stimulating hair growth
US5925657A (en) Use of PPARγ agonists for inhibition of inflammatory cytokine production
DE69634900T2 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
Yang et al. Effectiveness of the PPARγ agonist, GW570, in liver fibrosis
DE60223063T2 (de) C-kit inhibitoren
CA2425771A1 (fr) Ouvreurs selectifs de canaux potassiques maxi-k, fonctionnant sous des conditions de concentration calcique intracellulaire elevee, procedes et utilisations associes
JP2539257B2 (ja) Ｐａｆ―アセッサ―拮抗剤による疾患の治療
JPWO2003024446A1 (ja) 酸化ストレス抑制剤および酸化ストレスの測定方法
TWI306760B (en) Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
Hertzman et al. Repeated coronary artery spasm in a young woman with the eosinophilia-myalgia syndrome
Adamus et al. Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects
US6972175B2 (en) Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
Fahey et al. Effect of dicumarol on Ac-globulin and prothrombin activity.
JP2002542280A (ja) 新規な治療
Yamazaki et al. Enhancement of ADP-induced platelet aggregation by adrenaline in vivo and its prevention
US7056908B2 (en) Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
US20040132635A1 (en) Method for prevention and treatment of kidney diseases
US20040034045A1 (en) Inhibitors of thrombin induced platelet aggregation
DE69826287T2 (de) Verwendung von phospholambanhemmer zur steigerung der koronäre durchblutung
Gastpar et al. The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo: Effect of the Sulfonyl Urea Derivatives, Glibenclamide, Gliclazide, and HB 180, as Well as the Carboxylic Acid Derivative, Meglitinide

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20080205